[1]许兆延,杨希立.基质金属蛋白酶检测评价支架内再狭窄的意义[J].介入放射学杂志,2011,(05):363.
 XU Zhao-yan,YANG Xi-li..The value of matrix metalloproteinase in predicting the in-stent restenosis after percutaneous coronary intervention procedure[J].journal interventional radiology,2011,(05):363.
点击复制

基质金属蛋白酶检测评价支架内再狭窄的意义()

PDF下载中关闭

分享到:

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
期数:
2011年05期
页码:
363
栏目:
心脏介入
出版日期:
2011-05-30

文章信息/Info

Title:
The value of matrix metalloproteinase in predicting the in-stent restenosis after percutaneous coronary intervention procedure
作者:
许兆延 杨希立
528000  广东省  佛山市第一人民医院心血管内科
Author(s):

XU Zhao-yan YANG Xi-li.

Department of Cardiology, Foshan No. 1 Municipal People’s Hospital, Foshan, Guangdong Province 528000, China

关键词:
基质金属蛋白酶 经皮冠脉介入术 再狭窄 血管内超声 冠状动脉造影术
分类号:
R543.3
文献标志码:
A
摘要:
目的 探讨动态检测基质金属蛋白酶(MMP)1、MMP9在经皮冠脉介入术后再狭窄的意义。方法 对206例经皮冠脉介入(PCI)术后患者进行造影及冠脉血管内超声(IVUS)检查随访,造影证实再狭窄组32例,共38处病变;无再狭窄组174例,共229处病变。测量并比较两组外弹力膜横截面积、斑块面积、最小管腔面积及内膜增生面积;术前及随访时均行MMP检测,比较两组PCI前后MMP1、MMP9变化;按最小管腔面积(MLA)分为MLA > 5 mm2、MLA 3 ~ 5 mm2及MLA < 3 mm2组,比较3组的MMP1、MMP9水平。结果  与无再狭窄组比较,再狭窄组有更大的斑块面积、内膜增生面积及更少的最小管腔面积;两组患者术前及术后的MMP1水平无明显差异,无再狭窄组PCI前后MMP9水平无明显差异,再狭窄组术后MMP9明显升高,手术前后分别为(2.03 ± 0.56)ng/ml 比 (2.89 ± 0.33)ng/ml(P < 0.05);MMP1水平与MLA面积无关;MMP9水平在MLA > 5 mm2组明显低于MLA 3 ~ 5 mm2及MLA < 3 mm2,各为(1.45 ± 0.32)ng/ml、(2.93 ± 0.45)ng/ml 和 (3.09 ± 0.65)ng/ml,三组间差异有统计学意义(P < 0.05);后两组比较差异无明显统计学意义(P > 0.05)。结论  PCI后支架内再狭窄患者MMP9水平较术前升高,但与再狭窄程度无关。

参考文献/References:

[1] Mitra AK, Agrawal DK. In stent restenosis: bane of the stent era[J]. J Clin Pathol, 2006, 59: 232 - 239.
[2] Mintz GS. Features and parameters of drug-eluting stentdeploy-ment discoverable by intravascular ultrasound[J]. Am J Cardiol, 2007, 100(8B): 26M - 35M.
[3] Teirstein PS, Massullo V, Jani S, et al. Catheter-based radio-therapy to inhibit restenosis after coronary stenting[J]. N Engl J Med, 1997; 336: 1697 - 1703
[4] Schartl M, Bocksch W. How to assess coronary artery remodeling by intravascular ultrasound[J]. Am Heart J, 2006, 152(3): 414 - 416.
[5] Bonello L, De Labriolle A, Lemesle G et al. Arch Cardiovasc Dis. 2009, 102(2): 143 - 151.
[6] Jones GT, Kay IP, Chu JW. Elevated plasma active matrix -metal-lop-roteinase-9 level is associated with coronary artery in-stent restenosis[J]. Arterioscler Thromb Vasc Biol, 2006, 26 e121 - e125.
[7] 韩 健, 郭富强. 经皮腔内血管成形术后再狭窄的炎症预测因子[J]. 介入放射学杂志, 2009, 18 : 876 - 879.
[8] Raffetto JD, Khalil RA. Matrix metalloproteinases and their inhib -itors in vascular remodeling and vascular disease[J]. Biochem Pharmacol, 2008 , 75: 346 - 359.
[9] Katsaros KM, Kastl SP, Zorn G, et al. Increased restenosis rate after implantation of drug-eluting stents in patients with elevated serum activity of matrix metalloproteinase-2 and-9[J]. JACC Cardiovasc Interv, 2010, 3: 90 - 97.
[10] Jones GT, Tarr GP, Phillips LV, et al. Active matrix metallo-proteinases 3 and 9 are independently associated with coronary artery in-stent restenosis[J]. Atherosclerosis, 2009, 207: 603 - 607.

相似文献/References:

[1]肖运平,肖恩华,罗建光,等.化疗栓塞对肝细胞癌MMP-2、TIMP-2表达的影响[J].介入放射学杂志,2008,(11):784.
 XIAO Yunping,XIAO Enhua,LUO Jianguang,et al.The effect of chemoembolization on MMP-2and TIMP-2expressions of hepatocellular carcinoma[J].journal interventional radiology,2008,(05):784.
[2]胡健,陆林,吴立群,等.基质金属蛋白酶基因1、2、3和9多态性与冠状动脉粥样斑块进展关系的研究[J].介入放射学杂志,2009,(12):888.
 HU Jian,LU Lin,WU Liqun,et al.The relationship of the gene polymorphisms of matrix metalloproteinase-1,-2,-3and-9to the progression of coronary atherosclerotic plaque[J].journal interventional radiology,2009,(05):888.
[3]毕永华,伊梦飞,陈红梅,等.国产弹性蛋白酶浸泡法构建兔腹主动脉瘤及其随访[J].介入放射学杂志,2020,29(04):376.
 BI Yonghua,YI Mengfei,CHEN Hongmei,et al.Establishment of abdominal aortic aneurysm induced by domestic elastase in experimental rabbit and follow-up observation[J].journal interventional radiology,2020,29(05):376.

备注/Memo

备注/Memo:
收稿日期:20101007
更新日期/Last Update: 2011-05-30